Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5435MR)

This product GTTS-WQ5435MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	WP_009902072.1
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	57299391
UniProt ID	P16154

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5435MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ3214MR	IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	ARGX-110
GTTS-WQ14681MR	IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	SCT-400
GTTS-WQ815MR	IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	ABBV-085
GTTS-WQ9104MR	IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	IMCgp100
GTTS-WQ4339MR	IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	BIW-8405
GTTS-WQ9607MR	IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	JNJ-61610588
GTTS-WQ8768MR	IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	IBI-101
GTTS-WQ10547MR	IVTScrip™ mRNA-Anti-IL23A, LY3074828(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	LY3074828

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST